DOI QR코드

DOI QR Code

약물방출 관상동맥 스텐트 시술 후 스텐트 혈전증 발생 환자의 임상경과

Clinical Outcomes of Stent Thrombosis after Drug-Eluting Coronary Stent Implantation

  • 김인수 (동신대학교 방사선학과) ;
  • 정명호 (전남대학교병원 심혈관센터) ;
  • 한재복 (동신대학교 방사선학과) ;
  • 장영일 (광양보건대학교 방사선과) ;
  • 장성주 (동신대학교 방사선학과)
  • 투고 : 2013.10.07
  • 심사 : 2013.12.02
  • 발행 : 2013.12.28

초록

약물방출 스텐트 (drug-eluting stents, DES)는 일반금속 스텐트에 비하여 재협착을 현저하게 줄었지만, DES의 구조적인 특성으로 인한 스텐트 혈전증 (stent thrombosis, ST)이 증가한다고 알려져 있다. 혈전증 유형의 정의는 Early ST ; (EST)은 30일 이내, Late ST ; (LST)은 31일 이상에서 1년 이내 그리고 Very late ST ; (VLST)은 1년 이상으로 분류 하였다. 스텐트 세대별 (시장 출시와 스텐트 디자인, Polymer 향상에 따른) ST발생빈도, 임상 양상 및 예후를 알아보았다. 2003년 6월부터 2013년 6월까지의 전남대학교병원 심혈관센터에서 경피적 관상동맥 중재술을 시행 받은 10,273명 중 ST 발생은 134명 (1.30%) 이었다. 세대별 발생빈도는 1세대에서 81명 (0.79%)으로 높았으며, 세대별 ST 유형은 1세대에서는 VLST의 발생률이 높았고 (p=0.002), 2세대에서는 EST와 LST의 발생률이 높았지만 (p=0.025), 3세대에서는 유의한 차이가 없었다(p=0.278). ST로 인하여 사망한 14명은 EST 10명 (18.2%), LST 2명 (8.3%), VLST 2명 (3.6%)로서 EST에서 사망률이 높았다 (p=0.042). DES 시술 후 발생하는 ST는 1.3% 이였고, VLST는 1세대 스텐트에서 많았으며, 입원 중 사망률은 EST에서 높았다.

Stent thrombosis after successful drug-eluting stent(DES) implantation has been reported in around 1% of patients in clinical trials. However, the increased risk of ST associated with DES remains a matter of concern. From 1 June 2003 to 30 June 2013, we investigated clinical characteristics, in-hospital outcomes in 10,273 patients who underwent percutaneous coronary intervention in the Heart Center of CNUH. Overall incidence of ST was 1.30% (134 patients). The incidence of ST according to the stent generations and the timing of ST (n=total, early vs. late vs. very late) were 0.79% (n=81, 26 vs. 12 vs. 43) in first-generation, 0.38% (n=39, 21 vs. 9 vs. 9) in second-generation and 0.14% (n=14, 8 vs 3 vs. 3) in third-generation, (p=0.70). The mortality from ST was significantly higher in early ST group compared to the late and very late ST groups (18.2% vs. 8.3% vs. 3.6%, p=0.042). Overall incidence of ST after DES implantation was 1.30% (134 patients). The in-hospital mortality was significantly higher in early ST group compared to the late and very late ST groups.

키워드

참고문헌

  1. D. R. jr. Holmes, M. B. Leon, J. W. Moses, J. J. Popma, D. Cutlip, and P. J. Fitzgerald, "Analysis of 1-year clinical out comes in the SIRIUS trial: a randomized trial of a sirolimus -eluting stent versus a standard stent in patients at high risk for coronary restenosis," Circulation, Vol.109, pp.634-640, 2004. https://doi.org/10.1161/01.CIR.0000112572.57794.22
  2. A. M. Salam, J. Suwaidi, and D. R. jr. Holmes "Drug-eluting coronary stents," Curr Probl Cardiol, Vol.31, pp.8-119, 2006. https://doi.org/10.1016/j.cpcardiol.2005.09.002
  3. M. B. Leon and A. Bakhai, "Drug-eluting stents glycoprotein IIb/IIIa inhibitors combination therapy for the future," J. Am Heart, Vol.146, pp.S13-7, 2003. https://doi.org/10.1016/j.ahj.2003.09.004
  4. G. S. Mintz, A. Tinana, M. K. Hong, C. W. Lee, J. J. Kim, and N. E. Fearnot, "Impact of preinterventional arterial remodeling on neointimal hyperplasia after implantation of (non-polymer-encapsulated) paclitaxelcoated stents: a serial volumetric intravascular ultrasound analysis from the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT)," Circulation, Vol.108, pp.1295-1298, 2013.
  5. J. R. Nebeker, R. Virmani, C. L. Bennett, J. M. Hoffman, M. H. Samore, and J. Alvarez, "Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project," J Am Coll Cardiol, Vol.47, pp.175-181, 2006. https://doi.org/10.1016/j.jacc.2005.07.071
  6. R. Virmani, A. Farb, G. Guagliumi, and F. D. Kolodgie, "Drug-eluting stents:caution and concerns for long-term outcome," Coron Artery Dis, Vol.15, pp.313-318, 2004. https://doi.org/10.1097/00019501-200409000-00003
  7. P. W. Serruys, B. van Hout, H. Bonnier, V. Legrand, E. Garcia, and C. "Macaya, Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)," Lancet, Vol.352, pp.673-681, 1998. https://doi.org/10.1016/S0140-6736(97)11128-X
  8. B. L.van der Hoeven, S. S. Liem, and J. W. Jukema, "Sirolimus-eluting stents versus bare-metal stents in patients with ST -segment elevation myocardia infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study," J Am Coll Cardiol, Vol.51, pp.618-626, 2008. https://doi.org/10.1016/j.jacc.2007.09.056
  9. N. Guo, A. Maehara, and G. S. Mintz, "Incidence, mechanisms, predictors and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction:an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial," Circulation, Vol.122, pp.1077-1084.
  10. G. Nakazawa, A. V. Finn, and M. Joner, "Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients an autopsy study," Circulation, Vol.118, pp.1138-1145, 2008. https://doi.org/10.1161/CIRCULATIONAHA.107.762047
  11. S. Cook, P. Wenaweser, M. Togni, M. Billinger, C. Morger, C. Seiler, R. Vogel, O. M. Hess, B. Meier, and S. Windecker, "Incomplete stent apposition and late stent thrombosis followingdrug-eluting stent implantation," Circulation, Vol.115, pp.2426-2434, 2007. https://doi.org/10.1161/CIRCULATIONAHA.106.658237
  12. R. Virmani, G. Guagliumi, A. Farb, G. Musumeci, N. Grieco, T. Motta, L. Mihalcsik, M. Tespili, O. Valsecchi, and F. D. Kolodgie, "Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent," Circulation, Vol.109, pp.701-705, 2004. https://doi.org/10.1161/01.CIR.0000116202.41966.D4
  13. J. R. Nebeker, R. Virmani, C. L. Bennett, J. M. Hoffman, M. H. Samore, J. Alvarez, C. J. Davidson, J. M. McKoy, D. W. WRaisch, B. K. Whisenant, P. R. S. M. Yarnold, D. P. Belknap, J. E. West, Gage, R. E. G. F. Morse Gligoric, L. Davidson, and M. D. Feldman, "Hypersensitivity cases associated with drug-eluting coronary stents," J Am Coll Cardiol, Vol.47, pp.175-181, 2006. https://doi.org/10.1016/j.jacc.2005.07.071
  14. M. J oner, A. V. Finn, A. Farb, E. K. Mont, F. D. Kolodgie, E. Ladich, R. Kutys, K. Skorija, H. K. Gold, and R. Virmani, "Pathology of drugeluting stents in humans," J Am Coll Cardiol, Vol.48, pp.193-202, 2006. https://doi.org/10.1016/j.jacc.2006.03.042
  15. I. S. Kim, N. G. Choi, J. B. Han, S. J. Jang, and Y. I. Jang, "Clinical outcome of stent thrombosis in patients with acute myocardial infarction," J. of Contents Association, Vol.12, No.7, pp.273-283, 2012.
  16. D. E. Cutlip, S. Windecker, and R. Mehran, "Clinical end points in coronary stent trials: a case for standardized definitions," Circulation, Vol.115, pp.2344-2351, 2007. https://doi.org/10.1161/CIRCULATIONAHA.106.685313
  17. D. E. Cutlip, D. S. Baim, K. K. Ho, J. J. Popma, A. J. Lansky, D. J. Cohen, J. P. jr Carrozza, M. S. Chauhan, O. Rodriguez, and R. E. Kuntz, "Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials," Circulation, Vol.103, pp.1967-1971, 2001. https://doi.org/10.1161/01.CIR.103.15.1967
  18. J. M. Brennan, J. P. Curtis, D. Dai, S. Fitzgerald, A. K. Khandelwal, J. A. Spertus, S. V. Rao, M. Singh, R. E. Shaw, K. K. Ho, R. J. Krone, W. S. Weintraub, W. D. Weaver, and E. D. Peterson, "National Cardiovascular Data Registry. Enhanced Mortality Risk Prediction With a Focus on High-Risk Percutaneous Coronary Intervention: Results From 1,208,137 Procedures in the NCDR(National Cardiovascular Data Registry)," JACC Cardiovasc Interv, Vol.6, No.8, pp.790-799, 2013. https://doi.org/10.1016/j.jcin.2013.03.020
  19. J. Daemen, P. Wenaweser, K. Tsuchida, L. Abrecht, S. Vaina, C. Morger, N. Kukreja, P. Jüni, G. Sianos, G. Hellige, R. T. van Domburg, O. M. Hess, E. Boersma, B. Meier, S. Windecker, and P. W. Serruys, "Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study," Lancet, Vol.369, pp.667-678, 2007. https://doi.org/10.1016/S0140-6736(07)60314-6
  20. K. W. Park, S. J. Hwang, D. A. Kwon, B. H. Oh, Y. B. Park, I. H. Chae, H. C. Gwon, S. J. Park, K. B. Seung, T. Ahn, J. H. Yoon, Y. S. Jang, M. H. Jeong, S. J. Tahk, and H. S. Kim, "Korea Stent Thrombosis Investigators. Characteristics and predictors of drug-eluting stent thrombosis" results from the multicenter 'Korea Stent Thrombosis (KoST)' registry," Circ J, Vol.75, pp.1626-1632, 2011. https://doi.org/10.1253/circj.CJ-10-1160
  21. J. Daemen, P. Wenaweser, K. Tsuchida, L. Abrecht, S. Vaina, and C. Morger, "Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study," Lancet, Vol.369, pp.667-678, 2007. https://doi.org/10.1016/S0140-6736(07)60314-6
  22. G. W. Stone, J. W. Moses, S. G. Ellis, J. Schofer, K. D. Dawkins, and M. C. Morice, "Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents," N Engl J Med, Vol.356, pp.998-1008, 2007. https://doi.org/10.1056/NEJMoa067193
  23. L. Mauri, W. H. Hsieh, J. M. Massaro, K. K. Ho, R. D'Agostino, and D. E. Cutlip, "Stent thrombosis in randomized clinical trials of drug-eluting stents," N Engl J Med, Vol.356, pp.1020-1029, 2007. https://doi.org/10.1056/NEJMoa067731
  24. A. T. Ong, A. Hoye, J. Aoki, C. A. van Mieghem, G. A. Rodriguez Granillo, and K. Sonnenschein, "Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation," J Am Coll Cardiol, Vol.45, pp.947-953, 2005. https://doi.org/10.1016/j.jacc.2004.09.079
  25. A. A. Bavry, D. J. Kumbhani, T. J. Helton, and D. L. Bhatt, "Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention," Am J Cardiol, Vol.95, pp.1469-1472, 2005. https://doi.org/10.1016/j.amjcard.2005.02.015
  26. A. A. Bavry, D. J. Kumbhani, T. J. Helton, and D. L. Bhatt, "What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?," J Am Coll Cardiol, Vol.245, pp.941-946, 2005.
  27. A. Kastrati, J. Mehilli, J. Pache, C. Kaiser, M. Valgimigli, and H. Kelbaek, "Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents," N Engl J Med, Vol.356, pp.1030-1039, 2007. https://doi.org/10.1056/NEJMoa067484
  28. D. W. Park, S. W. Park, K. H. Park, B. K. Lee, Y. H. Kim, and C. W. Lee, "Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up," Am J Cardiol, Vol.98, pp.352-356, 2006. https://doi.org/10.1016/j.amjcard.2006.02.039
  29. I. Iakovou, T. Schmidt, E. Bonizzoni, L. Ge, G. M. Sangiorgi, and G. Stankovic, "Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents," JAMA, Vol.293, pp.2126-2130, 2005. https://doi.org/10.1001/jama.293.17.2126
  30. A. T. Ong, A. Hoye, J. Aoki, C. A. van G. A. Mieghem, Rodriguez Granillo, and K. Sonnenschein, "Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation," J Am Coll Cardiol, Vol.45, pp.947-953, 2005. https://doi.org/10.1016/j.jacc.2004.09.079
  31. J. M. Lasala, D. A. Cox, D. Dobies, K. Baran, W. B. Bachinsky, and E. W. Rogers, "Drug-eluting stent thrombosis in routine clinical practice: Two-year outcomes and predictors from the TAXUS ARRIVE registries," Circ Cardiovasc Interv, Vol.2, pp.285-293, 2009. https://doi.org/10.1161/CIRCINTERVENTIONS.109.852178.109.852178
  32. F. Airoldi, A. Colombo, N. Morici, A. Latib, J. Cosgrave and L. Buellesfeld, "Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment," Circulation, Vol.116, pp.745-754, 2007. https://doi.org/10.1161/CIRCULATIONAHA.106.686048
  33. Y. S. Ahn, J. H. Cho, D. H. Kim, Y. J. Hwang, H. M. Jung, and M. S. Choi, "A fatal case of simultaneous, very late thrombosis involving three drug-eluting stents in three coronary arteries," Korean Circ J, Vol.38, pp.564-569, 2008. https://doi.org/10.4070/kcj.2008.38.10.564
  34. O. K. Siddiqi and D. P. Faxon, "Very late stent thrombosis: current concepts," Curr Opin Cardiol, Vol.27, pp.634-641, 2012. https://doi.org/10.1097/HCO.0b013e3283587c7e
  35. K. Sudhir, J. B. Hermiller, J. M. Ferguson, and C. A. Simonton, "Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion and Stent Related Factors and Dual Antiplatelet Therapy," ISRN Cardiol, Vol.748736, 2013(6).
  36. G. G. Stefanini, B. Kalesan, P. W. Serruys, D. Heg, P. Buszman, A. Linke, T. Ischinger, V. Klauss, F. Eberli, W. Wijns, M. C. Morice, C. Di Mario, R. Corti, D. Antoni, H. Y. Sohn, P. Eerdmans, G. A. van Es, B. Meier, S. Windecker, and P. Juni, "Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial," Lancet, Vol.378, pp.1940-1948, 2011. https://doi.org/10.1016/S0140-6736(11)61672-3
  37. H. Kitabata, J. P. Loh, L. K. Pendyala, S. Badr, D. Dvir, I. M. Barbash, S. Minha, R. Torguson, F. Chen, L. F. Satler, W. O. Suddath, K. M. Kent, A. D. Pichard, and R. Waksman, "Safety and efficacy outcomes of overlapping second generation everolimus eluting stents versus first generation drug eluting stents," Am J Cardiol, Vol.112, No.8, pp.1093-1098, 2013(10). https://doi.org/10.1016/j.amjcard.2013.05.054

피인용 문헌

  1. Long-term Clinical Outcomes after Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction-on the basis of 65 Years vol.14, pp.5, 2014, https://doi.org/10.5392/JKCA.2014.14.05.251
  2. Development and Evaluation of a Self Care Education Program for Elderly Patients with Percutaneous Coronary Intervention vol.20, pp.2, 2014, https://doi.org/10.5977/jkasne.2014.20.2.266